Harte Hanks (HHS, Financial) has acquired the exclusive rights to license the Medical Ailment Database from ADS Data Direct, with certain client exceptions. This strategic move establishes Harte Hanks as the steward of one of the most extensive, HIPAA-compliant health data collections available to healthcare marketers. The database, derived from Healthier Me Today, includes data from fully triple opt-in consumers who have self-reported their health conditions across over 200 ailment categories.
This significant data asset enhances Harte Hanks' capabilities in improving targeting accuracy, boosting campaign outcomes, and ensuring compliance for clients in the pharmaceutical, medical device, and broader healthcare industries.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Harte-Hanks Inc (HHS, Financial) is $17.50 with a high estimate of $17.50 and a low estimate of $17.50. The average target implies an upside of 288.89% from the current price of $4.50. More detailed estimate data can be found on the Harte-Hanks Inc (HHS) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Harte-Hanks Inc's (HHS, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
